肥胖作为慢性肾脏病患者可干预的危险因素
本文综述肥胖与代谢综合征在慢性肾脏病(CKD)中的病理生理机制及治疗进展。识别CKD进展和心血管事件高风险表型,SGLT2抑制剂、GLP-1受体激动剂及非奈利酮联合标准RAS阻断展现心肾保护潜力,强调多学科综合管理。
要点
- 肥胖与代谢综合征协同增加CKD患者心血管和肾脏并发症风险。
- SGLT2抑制剂、GLP-1受体激动剂及非奈利酮联合RAS阻断具心肾保护潜力。
- 需识别高风险表型并采取多靶点、多学科整合管理策略。
核心结论
- 肥胖是CKD可干预的危险因素,多靶点治疗策略有望改变疾病进展自然病程并改善患者结局。
研究设计与样本
- 本文为综述,总结肥胖与CKD相互作用及治疗进展,未报告系统检索范围。
主要发现
- 肥胖与代谢综合征常共存并协同增加心血管和肾脏并发症风险。
- 识别与CKD进展和心血管事件高风险相关的不同表型有助于临床管理。
- SGLT2抑制剂、GLP-1受体激动剂及与菲奈利酮联合标准RAS阻断在肥胖和/或代谢综合征合并CKD患者中显示心肾保护潜力。
临床怎么用
- 对肥胖合并CKD患者,可在标准RAS阻断基础上考虑SGLT2抑制剂、GLP-1受体激动剂及非奈利酮等多靶点治疗。
- 需采用多学科整合方法管理肥胖与CKD共存患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity and metabolic syndrome (MS) represent two of the most pressing global public health challenges, often coexisting and synergistically increasing the risk of cardiovascular and renal complications. Over the past decade, advances in our understanding of the pathophysiological mechanisms underlying chronic kidney disease (CKD) have reshaped our approach to patients with coexisting obesity and CKD. The identification of distinct phenotypes associated with an elevated risk of CKD progression and cardiovascular events, along with the development of novel therapeutic strategies, has contributed to a paradigm shift in clinical management. Currently, therapeutic options such as sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and their combination with the non-steroidal mineralocorticoid receptor antagonist finerenone-when added to standard renin-angiotensin-aldosterone system blockade-are available and have shown potential for cardiorenal protection in patients with obesity and/or MS and CKD. In this review, we highlight the complex interplay between obesity and CKD, emphasizing the need for an integrated, multidisciplinary approach. The use of multitargeted therapeutic strategies holds promise in substantially altering the natural course of disease progression, ultimately improving patient outcomes.
引用
- Morales E, Jenssen TG, Bevc S, et al. Obesity as a modifiable risk factor in patients with chronic kidney disease. Nephrol Dial Transplant. 2026. PMID: 41165722. doi:10.1093/ndt/gfaf231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。